Intelligent Bio Solutions reported a 132.4% surge in its share price after signing a multi-year manufacturing agreement with a leading contract development and manufacturing organization. The deal guarantees a 30% reduction in per-unit production costs for the company’s flagship fingerprint-based drug screening cartridges, boosting gross margins by an estimated 15 percentage points. Under the partnership, output capacity will scale from 50,000 to 200,000 test cartridges per month, supporting the planned entry into U.S. occupational testing markets in mid-2026. Management forecasts annual cost savings of $4.2 million and expects the arrangement to accelerate regulatory filings by two quarters.

On December 31, Intelligent Bio Solutions closed a private placement raising approximately $10.0 million in gross proceeds through the sale of 2,298,850 common shares and an equal number of Series K-1 and K-2 warrants. Ladenburg Thalmann & Co. served as exclusive placement agent. The warrants carry an exercise price of $4.10 and five-year terms once a related registration statement is declared effective. Net proceeds will fund working capital and corporate growth initiatives, including expanded marketing efforts for European and Asia Pacific deployments and scaled hiring for the U.S. launch team. The closing is expected January 2, 2026, subject to customary conditions.